Sanofi’s shifting shape of R&D during Reed’s tenure

R&D head John Reed is leaving Sanofi as the pharma prepares to launch two products developed under his watch, with more programs across key therapeutic areas advancing behind them in the pipeline. But the company has yet to complete a transition laid out early in his five-year tenure under the leadership of Paul Hudson, as it remains heavily reliant on Dupixent and grapples with some uncertainty in oncology, an area it had earmarked for investment.

Sanofi (Euronext:SAN; NASDAQ:SNY) said Monday that Reed would leave his role for an outside opportunity, which later in the day was revealed to be the top R&D post at Johnson & Johnson (NYSE:JNJ). CMO and Global Head of Development Dietmar Berger will fill his position on an interim basis...